Preprint
via Europe PMC
Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
· 2026
Loss of proteostasis
Mitochondrial dysfunction
Stem-cell exhaustion
Altered intercellular communication
Chronic inflammation
Human
Preclinical / animal
Review
Abstract
Skeletal muscle aging arises from interacting defects in proteostasis(definition), mitochondrial quality control, inflammatory signaling, neuromuscular integrity, regenerative capacity, and mechanical-metabolic plasticity, and may culminate in sarcopenia. Circular RNAs (circRNAs) are plausible regulators and biomarker candidates, but most evidence derives from developmental myogenesis, expression profiling, or non-aging atrophy models. This critical review organizes the literature around skeletal muscle aging and applies a four-level framework encompassing discovery, mechanistic support, in vivo causality, and functional intervention. We assess human linkage, species, treatment timing, locus of action, and endogenous or engineered modality separately. circSnd1 and circDdb1 currently provide the strongest combination of functional preclinical evidence and association with aged human skeletal muscle. circFUT10, circBBS9, circNEB, and circGLIS3 define less mature regenerative, discovery, histological, or muscle-quality domains. Non-aging atrophy studies, including circTmeff1 and engineered circmiR-29b, test whether proposed mechanisms remain active under defined catabolic stress. In the targeted literature reviewed here, no reported circulating circRNA has yet met the analytical, biological, and clinical requirements for a useful sarcopenia biomarker. Therapeutic development is constrained by quantitative target credibility, systemic skeletal-muscle exposure, post-onset functional efficacy in aged organisms, safety, reversibility, and independent replication. The field should now prioritize rigorous validation over additional descriptive cataloging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.20944/preprints202609.1313.v1
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
THP, N., & W., L. (2026). Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness. https://doi.org/10.20944/preprints202609.1313.v1
Vancouver
THP N, W. L. Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness. 2026. doi:10.20944/preprints202609.1313.v1.
BibTeX
@unpublished{ngo2026Circul,
title = {Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness},
author = {Ngo THP and Lee W.},
year = {2026},
doi = {10.20944/preprints202609.1313.v1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International journal of molecular sciences 2026
Open access · OA
Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness.
International Journal of Molecular Sciences 2026
Open access · CC-BY
Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
International journal of molecular sciences 2026
Open access · OA
Circular RNAs in Skeletal Muscle Aging and Sarcopenia: Mechanistic Evidence, Biomarker Potential, and Therapeutic Readiness
Ageing Research Reviews 2026
Open access · CC-BY
Age-related sarcopenia and the gut microbiome: mechanistic insights into the gut-muscle axis and potential microbiome based therapeutic interventions
Food Frontiers 2023
Open access · CC-BY
Targeting mitochondrial quality control in muscle aging: Natural dietary products as potential interventions
Pharmaceutics 2022
Open access · CC-BY